tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2023 Mar 29;11(4):753.
doi: 10.3390/vaccines11040753. Cost-Effectiveness of Vaccination of Older Adults with an MF59[SUP]®[/SUP]-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
Jorge Jacob[SUP] 1 [/SUP], Tor Biering-Sørensen[SUP] 2 3 [/SUP], Lars Holger Ehlers[SUP] 4 [/SUP], Christina H Edwards[SUP] 5 [/SUP], Kristin Greve-Isdahl Mohn[SUP] 6 7 [/SUP], Anna Nilsson[SUP] 8 [/SUP], Jonas Hjelmgren[SUP] 9 [/SUP], Wenkang Ma[SUP] 1 [/SUP], Yuvraj Sharma[SUP] 1 [/SUP], Emanuele Ciglia[SUP] 10 [/SUP], Joaquin Mould-Quevedo[SUP] 11 [/SUP]
Affiliations
Individuals aged 65 years and above are at increased risk of complications and death from influenza compared with any other age group. Enhanced vaccines, as the MF59[SUP]®[/SUP]-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (HD-QIV), provide increased protection for older adults in comparison to the traditional standard-dose quadrivalent influenza vaccines (SD-QIV). This study aimed to assess the cost-effectiveness of aQIV compared to SD-QIV and HD-QIV in Denmark, Norway, and Sweden for adults aged ≥65 years. A static decision tree model was used to evaluate costs and outcomes of different vaccination strategies from healthcare payer and societal perspectives. This model projects that compared to SD-QIV, vaccination with aQIV could prevent a combined total of 18,772 symptomatic influenza infections, 925 hospitalizations, and 161 deaths in one influenza season across the three countries. From a healthcare payer perspective, the incremental costs per quality adjusted life year (QALY) gained with aQIV versus SD-QIV were EUR 10,170/QALY in Denmark, EUR 12,515/QALY in Norway, and EUR 9894/QALY in Sweden. The aQIV was cost saving compared with HD-QIV. This study found that introducing aQIV to the entire population aged ≥65 years may contribute to reducing the disease and economic burden associated with influenza in these countries.
Keywords: Nordic countries; adjuvanted influenza vaccine; cost-effectiveness; seasonal influenza
. 2023 Mar 29;11(4):753.
doi: 10.3390/vaccines11040753. Cost-Effectiveness of Vaccination of Older Adults with an MF59[SUP]®[/SUP]-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
Jorge Jacob[SUP] 1 [/SUP], Tor Biering-Sørensen[SUP] 2 3 [/SUP], Lars Holger Ehlers[SUP] 4 [/SUP], Christina H Edwards[SUP] 5 [/SUP], Kristin Greve-Isdahl Mohn[SUP] 6 7 [/SUP], Anna Nilsson[SUP] 8 [/SUP], Jonas Hjelmgren[SUP] 9 [/SUP], Wenkang Ma[SUP] 1 [/SUP], Yuvraj Sharma[SUP] 1 [/SUP], Emanuele Ciglia[SUP] 10 [/SUP], Joaquin Mould-Quevedo[SUP] 11 [/SUP]
Affiliations
- PMID: 37112667
- DOI: 10.3390/vaccines11040753
Individuals aged 65 years and above are at increased risk of complications and death from influenza compared with any other age group. Enhanced vaccines, as the MF59[SUP]®[/SUP]-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (HD-QIV), provide increased protection for older adults in comparison to the traditional standard-dose quadrivalent influenza vaccines (SD-QIV). This study aimed to assess the cost-effectiveness of aQIV compared to SD-QIV and HD-QIV in Denmark, Norway, and Sweden for adults aged ≥65 years. A static decision tree model was used to evaluate costs and outcomes of different vaccination strategies from healthcare payer and societal perspectives. This model projects that compared to SD-QIV, vaccination with aQIV could prevent a combined total of 18,772 symptomatic influenza infections, 925 hospitalizations, and 161 deaths in one influenza season across the three countries. From a healthcare payer perspective, the incremental costs per quality adjusted life year (QALY) gained with aQIV versus SD-QIV were EUR 10,170/QALY in Denmark, EUR 12,515/QALY in Norway, and EUR 9894/QALY in Sweden. The aQIV was cost saving compared with HD-QIV. This study found that introducing aQIV to the entire population aged ≥65 years may contribute to reducing the disease and economic burden associated with influenza in these countries.
Keywords: Nordic countries; adjuvanted influenza vaccine; cost-effectiveness; seasonal influenza